Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

NCT02244827 | Completed Phase 1

• 1 other identifier: W-2349-102
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.

Conditions

Hepatic Impairment

Outcome Measures

Primary Outcomes (1)

• To compare the pharmacokinetics parameters -AUC,Cmax, tmax, λz, t1/2, systemic clearance and apparent volume of distribution.

  To compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 in patients with hepatic impairment and healthy volunteers

  48 hours

Secondary Outcomes (1)

• To evaluate the safety and tolerability parameters- Number of AE , Vital signs, clinical laboratory values, abnormal physical examinations and ECGs

  7 weeks

Study Arms (1)

WCK 2349

EXPERIMENTAL

Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.

Drug: WCK 2349

Interventions

WCK 2349 DRUG

levonadifloxacin (active drug) and the sulfate metabolite

Also known as: levonadifloxacin (active drug)

WCK 2349

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Body Mass Index (BMI): 18.0 - 38.0 (Body weight in kg / Height in m2), both inclusive.
• Subjects must fulfill the following criteria:
• Patients with hepatic impairment:
• Considered clinically stable in the opinion of the Investigator
• Patients with different degrees of impaired hepatic function as assessed by a Child-Pugh classification score: mild (5-6 points), moderate (7-9 points) and severe (10-15 points) impaired hepatic function.
• Documented history of cirrhosis diagnosed by liver biopsy, ultrasonography (USG), computed tomography (CT) scan, or magnetic resonance imaging (MRI) OR
• Healthy volunteers:
• Have normal hepatic function
• Participants with a history of self-limited hepatitis A with complete resolution documented at least 6 months prior to entry will be allowed

You may not qualify if:

• Known hypersensitivity to quinolones/fluoroquinolones.
• Subjects must not fulfill the following criteria:
• In hepatically impaired patients:
• Use of prohibited concomitant medication, with the exception of those essential for the management of hepatic impairment and the treatment of concomitant stable medical conditions for the hepatically impaired patients as per the discretion of the Investigator.
• Fluctuating or rapidly deteriorating hepatic function as indicated by recent history or widely varying or worsening of clinical and/or laboratory signs of hepatic impairment as judged by the Investigator.
• Concomitant treatment with Interferon or other prohibited medications
• Active stage 3 and stage 4 encephalopathy OR
• Healthy Volunteers:
• Use of any concomitant medication within 7 days from the screening except those deemed safe for the study by the Investigator and Medical Monitor.
• History of any clinically significant chronic and/or active hepatic disease including elevations of serum transaminases including aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \[except those which are considered non-significant by the Investigator; however, these should not exceed 1.5 times the Upper Limit of Normal (ULN)\], hepatitis (Hepatitis A, B or C), biliary tract disease, or history of any significant gastrointestinal surgery.

Sponsors & Collaborators

• Wockhardt: lead

Study Sites (1)

University of Miami,Division of Clinical Pharmacology

Miami, Florida, 33136, United States

Location

MeSH Terms

Interventions

levonadifloxacin

Study Officials

• Richard A Preston, M.D.

  Division of Clinical Pharmacology,University of Miami

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 10, 2014
• First Posted: September 19, 2014
• Study Start: September 1, 2014
• Primary Completion: December 1, 2014
• Study Completion: June 1, 2015
• Last Updated: October 29, 2015

Record last verified: 2015-10

Locations

US (1)